NasVax receives Ministry of Health Approval for a Phase 1/2a Clinical Study for Improved Flu Vaccine
NasVax Ltd., Israeli biotechnology company developing innovative biopharmaceutical products for improving immune responses and administration of vaccines, has announced that it received approval from the Helsinki Committee and the Israel Ministry of Health to perform a Phase 1/2a clinical study for its improved influenza vaccine, through the intramuscular route. The company initiated the clinical study in around 100 volunteers on July 11. This combination Phase 1/2a study addresses the safety and efficacy of the immune response to vaccination.
NasVax engages in the development of vaccines based on its technology platform for improving the immune response to vaccines and enabling both injection and intranasal administration. This technology utilizes CCS/C, a novel biocompatible adjuvant and delivery system, which has been shown to stimulate not only an increased antibody response but also produce a response in T-cells, hence further improved potency. This potent system opens the way for developing further product applications for preventing or treating both infectious and noninfectious diseases.
The company's adjuvant and delivery technology for improving vaccines is based on joint research by Professors Eli Kedar and Yechezkel Barenholz, co-inventor of a liposomal formulation of doxorubicin for cancer treatment, marketed in the USA by Johnson & Johnson (as DoxilTM) and in Europe by Schering Plough (as Caelyx).
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.